A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors [abstract 41] - Rinehart,J.J.; Wilding,G.; Willson,J. (Proc Am Soc Clin Oncol, 2002)